At the 2026 European Society for Medical Oncology (ESMO) Congress, AbbVie presented new and updated data on its oncology portfolio, including investigational drugs like Temab-A, ABBV-706, and ABBV-969. These drugs showed encouraging clinical activity and survival benefits across multiple cancers such as lung, colorectal, ovarian, and prostate. Notably, Temab-A demonstrated improved survival in colorectal and non-small cell lung cancer patients, while ABBV-706 showed strong responses in small cell lung cancer. This data underscores AbbVie's commitment to advancing targeted cancer therapies and supports ongoing Phase 3 trials to further evaluate these treatments' efficacy and safety.
As of Oct 19, 2026 05:21 WIB, AbbVie Inc (ABBV) is trading at USD 285.42 on Pluang, showing a 1-day gain of 1.34%. The company holds a substantial market cap of $504.37 billion and offers a dividend yield of 2.42%. This strong market presence coincides with AbbVie's ongoing advancements in its oncology portfolio highlighted at the 2026 ESMO Congress.
AbbVie increased its quarterly dividend to $1.73, raising its annual payout by 5.5% despite a 29% stock price rise this year, which lowers the yield to about 2.4%. The company’s dividend payout ratio is around 49.5% of adjusted earnings, supported by...
AbbVie unveiled 20 new scientific presentations at the 2026 United European Gastroenterology Week, highlighting long-term and real-world data for its inflammatory bowel disease (IBD) treatments SKYRIZI (risankizumab) and RINVOQ (upadacitinib). The da...
